BCRX Overview
Upcoming Projects (BCRX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (BCRX)
-
A Second View: Examining Biocryst's BCX9930 (oral Factor D inhibitor) for the treatment in patients with C3 Glomerulopathy
Ticker: BCRX
Executed On: Sep 22, 2022 at 09:30 AM EDT -
Examining Biocryst's BCX9930 (oral Factor D inhibitor) for the treatment in patients with C3 Glomerulopathy
Ticker: BCRX
Executed On: Sep 20, 2022 at 04:30 PM EDT
Expired Projects (BCRX)
-
Discussing BioCryst’s BCX10013 in treating paroxysmal nocturnal hemoglobinuria
Ticker: BCRX
Execute By: Feb 28, 2023
Upcoming & Overdue Catalysts (BCRX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (BCRX)
-
BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 to Treat Hemorrhagic Fever Virus Diseases
Ticker: BCRX
Occurred on: Jul 05, 2016 -
Study Results From Zika Virus Infected Mice Treated With BCX4430 to be Presented at WHO Conference
Ticker: BCRX
Occurred on: Mar 07, 2016 -
Phase 2b data of BCX4161(avoralstat) - OPuS-2 trial - for Hereditarry angioedema due early 1Q 2016
Ticker: BCRX
Occurred on: Feb 08, 2016 -
BioCryst Announces Results From OPuS-2
Ticker: BCRX
Occurred on: Feb 08, 2016
Strategic Initiatives (BCRX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!